Incorporating the Latest Therapeutic Strategies for HCC: Collaborating to Optimize Patient Outcomes

In this online program based on a dynamic CCO symposium from the 2019 AASLD Annual Meeting experts discuss evidence-based best practices in treating patients with advanced HCC. Watch the on-demand Webcast and download the slides now.

Share

Program Content

No activities added yet

Activities

Locoregional Therapy
Locoregional Therapy Optimization and Patient Selection in HCC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 10, 2019

Expires: November 08, 2020

First-line Therapy
Initial Systemic Therapy Options for Advanced, Unresectable HCC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 10, 2019

Expires: November 08, 2020

Second-Line Therapy
Optimal Treatment Sequence Following Disease Progression After Initial Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 10, 2019

Expires: November 08, 2020

Incorporating Immunotherapy
Incorporating Immune Checkpoint Inhibitors Into Treatment For Patients With HCC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 10, 2019

Expires: November 08, 2020

Faculty

cover img faculity

Anthony El-Khoueiry, MD

Associate Professor of Medicine
Division of Medical Oncology, Keck School of Medicine
Norris Comprehensive Cancer Center, University of Southern California
Los Angeles, California

cover img faculity

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Andrew X. Zhu, MD, PhD, FACP

Director, Liver Cancer Research
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Bristol Myers Squibb

Eisai

Exelixis

Merck Oncology